Member Info for Redtom

Notgreedy, Tak could ask for extension but I seriously doubt. If there is a bid, I totally agree that it will be rejected. But I just hope the details of it are made public knowledge. I would hate to read a Notification that merely says that Tak have walked away because they were rebuffed by Shire BoD. SP will yoyo heavily on any Tak announcement and I think it will yoyo significantly in both directions for quite a while after Tak have gone away. It does seem that Pharma M&A is back in favour for 2018 so there may be other approaches even if this falls flat on its face. As you say, this nag will give us one hell of a ride!

Continued..... e professionals flexibility in treating von Willebrand disease with an appropriate dose of von Willebrand factor, with or without recombinant factor VIII, based on each patient's unique needs."1,5 The approval of VONVENDI in surgical settings was based on results from a Phase 3 prospective, open-label, multicenter trial to evaluate the efficacy and safety of VONVENDI with or without recombinant FVIII treatment in elective surgical procedures in adults (age 18 years and older) diagnosed with severe VWD.1 Results from the study showed VONVENDI met its primary endpoint, demonstrating overall hemostatic efficacy assessed 24 hours after the last perioperative VONVENDI infusion or at completion of study visit, whichever occurred earlier.1 The overall median dosing frequency of once-daily was demonstrated to normalize hemostasis in appropriate patients.1 One study participant developed deep vein thrombosis three days after undergoing hip replacement surgery while receiving VONVENDI.1 In addition to the expanded use of VONVENDI, the updated Prescribing Information includes new information about pharmacokinetics and storage of VONVENDI. VONVENDI can be stored at refrigerated temperature 2�C to 8�C (36�F to 46�F) or room temperature not to exceed 30�C (86�F). Do not freeze. Store VONVENDI in the original box and protect it from extreme exposure to light.

Shire plc : FDA APPROVES VONVENDI� FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASE FDA APPROVES VONVENDI� [VON WILLEBRAND FACTOR (RECOMBINANT)] FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASE1 Expanded use for VONVENDI - the first and only purified recombinant von Willebrand factor - builds on previously approved on-demand treatment indication1 VONVENDI now offers an individualized approach to bleed control in appropriate patients undergoing surgery1 von Willebrand disease is the most common inherited bleeding disorder, affecting up to one percent of the U.S. population2 Cambridge, Ma. - April 17, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare disease, today announced the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD).1 VONVENDI is also indicated for on-demand treatment and control of bleeding episodes, and it is the first and only recombinant treatment for adults living with VWD, the most common inherited bleeding disorder.1,3-4 "The expanded approval of VONVENDI represents a new treatment option for the surgical setting that can be tailored to each patient's individual needs,"1,3-5 said Andreas Busch, Global Head of Research and Development, Shire. "It's an important milestone in support of our vision of personalizing treatment and helping to address unmet needs for people with bleeding disorders."1,3-5 People with VWD lack proper quantities of VWF or functioning VWF, and they may or may not have a secondary factor VIII (FVIII) deficiency.5 Since not every person with VWD or every bleed requires FVIII replacement, VONVENDI allows healthcare providers to dose recombinant VWF independent of recombinant FVIII based on clinical judgement for each patient, taking into account severity, site of bleeding, the patient's medical history and monitoring of appropriate clinical and laboratory measures.1 Independent dosing with VONVENDI offers an individualized approach to bleed control in appropriate patients undergoing surgery.1 "Persons with von Willebrand disease face a heightened risk of bleeding during surgery and may require factor treatment before, during or after surgery," said Michael Tarantino, M.D., Professor of Pediatrics and Medicine, University of Illinois College of Medicine, and Medical Director and President, The Bleeding and Clotting Disorders Institute. "For surgeries requiring repeated, frequent infusions with combined von Willebrand factor and factor VIII concentrates, an excessive rise in factor VIII levels may increase the risk of thromboembolic complications, such as blood clots.1,7 The expanded use for VONVENDI in surgical settings gives healthcar

I agree any announcement will be late. But we only have a week left anyhow. I would guess after the weekend so I'll go for Tuesday 24th as not taken yet!. It's quite possible that something could be leaked to the press over the weekend followed up by a formal announcement on Monday morning. I'm still of the opinion (say 60:40) that no bid will be made by Takeda. I think they will make their excuses (they have plenty of options) and back down. I would love to be wrong. Even a low ball offer (�37 - 40) would be great as it would really alert the market. Given there seems to be a lot of M&A in the pharma industry this year (after next to none last year), any offer is bound to get others thinking. A rival bid would then put us into the acceptable territory range (�40-45). But most of this is wishful thinking on my part.

Where-is, My last message was tongue in cheek but may have come across as a serious response. It wasn't. ;-)

We're not talking it down. We're merely talking about why it has fallen on a daily basis. Don't shoot the messenger.

Good point scfc. And I also agree that this is all SPECULATION and none of us know any facts. Just our opinion.

This opened at 3732p and is now around 3536p. That's one hell of a change in sentiment given there has been no new news since opening. People know something but not everyone.

Looks like the markets are coming to the same conclusion that it is now highly unlikely that Takeda will make a formal bid. The sale of Oncology this morning, the current �:$ fx rate and the respective difference in SP has scuppered this deal. All in my opinion only but I just can't see any scenario where this works. If I was a Takeda shareholder, I would be bailing or screaming at the BoD not to do the deal.

They assumed this was still a growth stock. But poor management and over paying for acquisitions has made this a slow growth if, if any growth. Hence turnover forecast fell from $20bn to $18bn for 2020. The markets had blind faith in the management but are now starting to realise that FO and the BoD are not up to the job.

Because a Takeda bid is less likely?

Scfc, I agree with you. To suggest that Takeda are only now starting to talk to its banks, shareholders and BoD is farcical and written by people who have not worked in large Plcs. From my own experience of working on M&A deals with plcs, the amount of work leading up to any announcement is vast and includes all related parties. The funding structure would have been modelled to death and stress-tested. Major shareholders would have been spoken to. The whole BoD would be aware. These stories are merely page fillers when there is nothing concrete to talk about. What they are not, is news!

Shares in biotech firm Shire have risen 1.5% after the company said it had agreed to sell its Oncology business. The sale of the unit - to French firm Servier for $2.4bn - could put off Japan's Takeda from making a takeover bid for Shire. The oncology unit is one of the businesses that Takeda is particularly interested in getting its hands on. Under UK takeover rules, Takeda has until 25 April to decide whether it is going to make a bid for Shire.

This would not have been public knowledge. I'm almost certain that Takeda would not have known. Shire would have been keen to get this signed as it forms a major part of their defence against this hostile potential bid. Takeda will have to re-think their strategy given a major asset has gone.

Putting aside the implications to the Takeda situation, the Oncology sale is a great deal. Cash receipt of $2.4bn. Cash = good news. Sold at 9.2 times turnover = That is a high multiple. Sold at 17+ times EBITDA = Very good value for Shire. I don't normally have many good words to say about FO, but he has done a good deal here.

Scfc, Yes, this is the nail in the coffin as far as Takeda is concerned. They will not make a bid given that the Oncology part was in their first line as to why they were considering a bid. In that same line was Neuroscience and it seems this will need to be spun out to fund the deal. There is not a 'cat in hell's chance' chance for Takeda to make a bid now. SP starting to drift as the market starts to realise this too.

"The proceeds from the transaction increase optionality and Shire's Board will consider returning the proceeds of the sale to shareholders through a shareholder-approved share buyback after the current offer period regarding Takeda's possible offer for Shire concludes." I missed this when writing my first comment. Quite unusual when they have so much debt. Trying to sweeten shareholders with a fat carrot given the Takeda situation.

Transaction details Under the terms of the agreement, Servier has agreed to acquire Shire's Oncology business for a total consideration of $2.4 billion, in cash, upon completion. In 2017, the Oncology business generated revenues of $262 million. The total consideration represents a revenue multiple of 9.2 times 2017 revenues. The transaction covers the transfer of Shire's Oncology business including in-market products ONCASPAR� (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to ONIVYDE� (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL, and early stage immuno-oncology pipeline collaborations. The gross assets that are the subject of the transaction are approximately $1.6 billion and the profits attributable to the assets being transferred are approximately $140 million, excluding depreciation, amortization and other direct and indirect costs. Transaction closing This transaction constitutes a Class 2 transaction for the purposes of the U.K. listing rules and, as such, Shire shareholder approval is not required. The transaction has been approved by the Board of Directors and is expected to close in the second or third quarter of 2018. Transaction background Shire's Board of Directors initiated the potential divestment of the Oncology business in December 2017. The process, which commenced in January 2018, identified multiple potential strategic buyers across the U.S., Europe and Japan.

Shire Announces Sale of Oncology Business to Servier for $2.4 Billion Sale of Oncology business unlocks embedded value within Shire's portfolio and sharpens focus on core areas reinforcing our leadership in rare diseases Oncology business provides Servier S.A.S. with an immediate presence in the U.S., enhancing its commitment to addressing unmet patient needs in oncology Dublin, Ireland - April 16, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) the leading global biotechnology company focused on rare diseases announces today that it has entered into a definitive agreement with Servier S.A.S. ("Servier") to sell its Oncology business for $2.4 billion. Shire's Oncology business includes in-market products ONCASPAR� (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to ONIVYDE� (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL and early stage immuno-oncology pipeline collaborations. Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented: "This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio. While the Oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire's longer-term strategy. We will continue to evaluate our portfolio for opportunities to unlock further value and sharpen our focus on rare disease leadership with selective disposals of non-strategic assets. "We are confident that Servier will continue to invest in this business and our colleagues who are expected to transfer as part of the transaction in order to meet the needs of cancer patients globally. "The proceeds from the transaction increase optionality and Shire's Board will consider returning the proceeds of the sale to shareholders through a shareholder-approved share buyback after the current offer period regarding Takeda's possible offer for Shire concludes." Olivier Laureau, Servier Group President, commented: "The acquisition of Shire's oncology franchise enables Servier to meet its strategic ambitions to become a global key player in oncology. As an essential step in the evolution of the Group, this acquisition allows us to establish a direct commercial presence in the United States, the world's leading pharmaceuticals market, and to strengthen our portfolio of marketed products in the territories where Servier is already present. Our goal is to bring these treatments to greater numbers of cancer patients around the world. We thoroughly look forward to welcoming Shire's oncology teams who will join Servier after the closing." Transaction details Under the terms of the agreement, Servier has agreed to acquire Shire's

Interesting development. Presumably pays down a little bit of the debt. But I wonder what Takeda make of this? I think they are big into Oncology?